Skip to content
Screener

AbbVie ABBV EV / EBITDA

EV / EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
31.3×-7.9×
Pfizer logo
PfizerPFE
12.9×—
Johnson & Johnson logo
Johnson & JohnsonJNJ
19×+5.2×
Amgen logo
AmgenAMGN
15.7×+0.7×
Cardinal Health logo
Cardinal HealthCAH
16.9×+4.4×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
22.4×—

Other financials

Income statement

See full
Revenue$17.0B+10.2%
Gross profit$12.7B+14.6%
Operating income$6.4B+31.4%
Net income$3.6B+285%
EPS (diluted)$2.03+290%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$435.06B+25.5%
P/E69×-23.2×
P/S6.8×+0.8×

Profitability

See full
Gross margin71.5%+0.5pp
Operating margin26.2%—
Net margin9.8%+3.3pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Calculated from AbbVie’s reported figures.

enterprise value/ebitda=19.8×

Based on the most recent quarter.

The source filing: AbbVie’s 10-Q, filed May 8, 2026. Open the filing →

Filed
May 8, 2026, 12:28 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001551152-26-000017

FAQ

What is AbbVie's EV / EBITDA?
AbbVie (ABBV) reported EV / EBITDA of 19.8× in Q4 2025.
What is the long-term trend for AbbVie's EV / EBITDA?
Over 4 years (2020 to 2025), AbbVie's EV / EBITDA has grown at a 8.0% compound annual growth rate (CAGR), from 14.6× to 19.8×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about AbbVie's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude